Breaking News

NW Bio Expands Production Agreements

By Kristin Brooks | January 27, 2014

Cognate to provide manufacturing and services for DCVax-L and DCVax-Direct

Northwest Biotherapeutics has entered into agreements for large-scale expansion of the manufacturing, storage, handling and distribution of its DCVax-L and DCVax-Direct products, with its long-time contract manufacturer, Cognate Bioservices. The agreement includes development of infrastructure and key systems, and execution of product validation work required for regulatory submissions.
 
Cognate will provide manufacturing and services for DCVax-L and DCVax-Direct. Additional agreements provide for a comprehensive scale-up program for expansion of the company's clinical programs in the U.S. and Europe, and compassionate use programs, as well as an extensive development program for long-term preparations for potential commercialization, including building the infrastructure, systems and logistics for product validations.
 
"We are excited to enter into a broad program to expand capacity and build large scale infrastructure, systems and operations under these Agreements with Cognate," said Les Goldman, senior vice president of business development at NW Bio. "Such a program is essential for our future success, and involves a major commitment of resources and time. Cognate is a world leader in such developments, with an unparalleled 12-year track record of regulatory and operational success with two dozen different cell product trials, and with clinical grade manufacturing of cell products on three continents. We could not have a better and more effective partner for this major undertaking."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks